Scientist I/II, Modality Engineering
TLDR
Design and characterize oligonucleotides, bioconjugates, and AAV therapeutics from discovery through analytical handoff to in vitro and in vivo teams.
Role Summary
Lexeo is hiring a hands-on Modality Engineering Scientist to design, synthesize, and characterize oligonucleotides, bioconjugates, and AAV therapeutics for our discovery pipeline. The scientist will advance molecules from design through analytical characterization and handoff to in vitro and in vivo teams, working across chemistry, molecular biology, and pharmacology. Reporting to the Head of Cardiac Research, this role joins cardiac, neuroscience, and non-clinical scientists developing therapies for genetic heart disease and offers broad experience in multidisciplinary biopharma research.
Primary Responsibilities
Required Skills and Qualifications
Preferred Skills and Qualifications
About LEXEO
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
Lexeo Therapeutics is a clinical-stage genetic medicine company focused on pioneering therapies for inherited cardiovascular diseases. Our lead program targets cardiomyopathy linked to Friedreich’s Ataxia, while we also tackle a range of genetically defined conditions, leveraging innovative science to drive impactful clinical solutions.